NEW YORK, NY / ACCESSWIRE / April 15, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Canoo Inc. (NASDAQ:GOEV)
CONTACT JAKUBOWITZ ABOUT GOEV:
https://claimyourloss.com/securities/canoo-inc-loss-submission-form/?id=14745&from=1
Class Period : August 18, 2020 - March 29, 2021
Lead Plaintiff Deadline : June 1, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's engineering services was not a viable business, would not provide meaningful revenue in 2021, and would not reduce operational risk; (ii) the Company would no longer be focused on its subscription-based business model; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
FibroGen, Inc. (NASDAQ:FGEN)
CONTACT JAKUBOWITZ ABOUT FGEN:
https://claimyourloss.com/securities/fibrogen-inc-loss-submission-form/?id=14745&from=1
Class Period : November 8, 2019 - April 6, 2021
Lead Plaintiff Deadline : June 11, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
3D Systems Corporation (NYSE:DDD)
CONTACT JAKUBOWITZ ABOUT DDD:
https://claimyourloss.com/securities/3d-systems-corp-loss-submission-form/?id=14745&from=1
Class Period : May 6, 2020 - March 1, 2021
Lead Plaintiff Deadline : June 8, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) 3D Systems lacked proper internal controls over financial reporting; and (2) as a result, 3D Systems' public statements were materially false and/or misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law